BioSpace News Archive

CEVEC Pharmaceuticals GmbH announced the signing of an agreement with UCB S.A. on the evaluation and use of CEVEC’s proprietary ELEVECTA Technology for the research, development, and manufacturing of Adeno-Associated Virus vectors for gene therapy applications.

Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD)

Paragon 28® is pleased to announce the launch of its Silverback™ Span Plating System, which was specifically designed to be used in combination with a structural allograft or a titanium cage in cases where a significant void is present at the talus and/or ankle joint.

RedShift BioAnalytics announced the appointment of Amol Chaubal to its Board of Directors.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101 has been selected for an oral presentation at the XIXth International Symposium on Retinal Degeneration (RD2021) being held in Nashville, Tenn., and virtually September 28 – October 2, 2021.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021.

REGENXBIO Inc. announced it will participate in the following investor conferences, which will each be held in a virtual meeting format.

Owens & Minor, Inc. announced that the company will participate in Baird’s 2021 Global Healthcare Conference on September 14, 2021.

Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced that members of its management team will present at the following investor conferences in September 2021.

Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it will be featured as a presenting company at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference.